New Data on Opioid Use Disorder Program at Society for Neuroscience Meeting

Ensysce CEO Invited Expert Speaker at Formulation & Delivery US 2024 Meeting

SAN DIEGO, CA / ACCESSWIRE / September 24, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in two upcoming meetings in October 2024.

October 5, 2024: New data will be presented in a poster session in collaboration with Sygnature Discovery at the Society for Neuroscience meeting in Chicago in the session for Addictive Drugs: Drug Tolerance, Dependence, and Toxicity. The poster entitled “Methadone ameliorates the effects of morphine withdrawal in a modified rat model of physical dependence” is the first study of its kind in a pre-clinical model to evaluate the efficacy of novel agents for treating Opioid Use Disorder (OUD). OUD affects 16 million people worldwide and can be attributed to 500,000 deaths each year.

Impact on Individuals

For individuals struggling with Opioid Use Disorder, this new data presents a glimmer of hope for more effective treatment options. Methadone has long been used in the management of opioid addiction, and this study provides insight into its potential in treating the withdrawal symptoms associated with opioid dependence. If successful, this research could potentially lead to improved outcomes and quality of life for those affected by OUD.

Global Impact

On a global scale, the impact of advancements in OUD treatment cannot be overstated. With millions of people worldwide suffering from this debilitating disorder, finding innovative and effective solutions is crucial in reducing the devastating consequences of opioid abuse. By investing in research and development in this area, we can work towards addressing a public health crisis that has far-reaching implications across communities and nations.

Conclusion

In conclusion, the presentation of new data on Opioid Use Disorder treatment at the upcoming Society for Neuroscience meeting marks a significant milestone in the ongoing efforts to combat opioid abuse and overdose. Ensysce’s dedication to developing novel solutions for pain relief is commendable, and the impact of their research has the potential to bring about positive change for individuals and communities affected by OUD. It is through continued collaboration and innovation in the pharmaceutical industry that we can hope to make a meaningful difference in the lives of those struggling with addiction.